Loading patent…
AssigneeJanssen Pharmaceuticals, Inc.
InventorsKurt Iver Kamrud, Nathaniel Stephen Wang, Martina Felderman, Nancy C. Carrico
Estimating the term…
The present disclosure generally relates to viral-based expression systems suitable for the production of molecule of interests in recombinant host cells. The disclosure particularly relates to nucleic acid constructs, such as expression vectors, containing a modified arterivirus genome or replicon RNA in which at least some of its original viral sequence has been deleted. Also included in the disclosure are viral-based expression vectors including one or more expression cassettes encoding heterologous polypeptides. In some embodiments, the expression cassettes are configured and positioned at defined locations on the viral genome so as to enable expression of the heterologous polypeptides in a tunable manner.
A nucleic acid molecule comprising a nucleotide sequence encoding a modified equine arterivirus (EAV) genome or replicon RNA, wherein the modified EAV genome or replicon RNA further comprises a gene encoding a polypeptide of interest, wherein the modified EAV genome or replicon RNA comprises a sequence fragment exhibiting at least 80% sequence identity to the sequence encoding open reading frame ORF7 of the wild-type sequence of EAV, and wherein the modified genome or replicon RNA is devoid of the sequence encoding ORF2a of the wild-type sequence of EAV.
Dependencies are inferred from the claim text.